Novel immunotherapeutic shows promise against chronic hepatitis B

A novel immunotherapeutic in early development for chronic hepatitis B (CHB), TG1050, has been shown to reach the clinical goals that are considered to be the hallmarks of a cure for CHB, according to results revealed today at The International Liver Congress™ 2015.

The hallmarks of a CHB cure are:

  • Elimination of HBsAg - the surface antigen of the hepatitis B virus, and
  • HBsAg seroconversion - which occurs when a specific antibody becomes detectable in the blood and the corresponding antigen becomes undetectable, in this case HBsAg

In the study, decrease of HBsAg and HBsAg seroconversion was achieved in 30% of TG1050-injected mice.

Earlier studies have proven that TG1050 is able to induce a robust, multi-specific and long-lasting immune response against the hepatitis B virus. These latest results, which show that TG1050 is able to decrease HBsAg and lead to anti-HBsAg seroconversion in HBV persistent mouse models, support the move to a first-in-man study and the start of clinical development.

Source: European Association for the Study of the Liver

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
COVID-19 increases chronic fatigue risk